Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot

Source Investing

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY).

The biotech firm’s shares jumped soared 13% in premarket trading following the announcement.

Novavax (NASDAQ:NVAX) disclosed last month that the trial had been paused after a participant who received the combination vaccine initially reported symptoms suggestive of motor neuropathy, which affects the nerves controlling muscle movement.

The company later submitted additional data to the FDA, clarifying that the participant’s symptoms were more accurately linked to amyotrophic lateral sclerosis (ALS), a neurological condition impacting nerve cells in the brain and spinal cord.

Novavax stated that assessments found no connection between the symptoms and its vaccine.

"We thank the FDA for their partnership and thorough review of the additional information provided as part of our response package," said Robert Walker, Chief Medical (TASE:PMCN) Officer of Novavax.

"The information provided to the FDA supported our assessment that the serious adverse event was not related to our vaccine. We plan to start our Phase 3 trial as soon as possible."

A clinical hold is an FDA directive that instructs a drug manufacturer to delay or halt a planned clinical study. The move triggered a sharp drop in Novavax shares last month.

Novavax then stated that it did not believe there was a confirmed link between its vaccine and the reported nerve damage in the patient.

Public health officials consider Novavax's protein-based COVID vaccine to be a valuable choice for individuals hesitant to receive the mRNA vaccines from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

Unlike mRNA technology, which prompts cells to produce proteins that stimulate an immune response to COVID, Novavax’s approach relies on protein-based technology—a well-established method used for years in vaccines against diseases like hepatitis B and shingles.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Nov 16, Mon
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
Nov 17, Tue
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
Yesterday 03: 33
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
placeholder
US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC MinutesThe US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
Author  FXStreet
Yesterday 10: 14
The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
8 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
goTop
quote